Emerging Markets

November 2012

Breast Cancer in Mexico

Report Authors
Natalia Reoutova, M.A., M.Sc.
Anouchka Seesaghur, M.Sc., Ph.D.

Introduction:

Over the next decade, the diagnosed  incidence of breast cancer (CaB) in Mexico will increase at almost three times the average annual growth rate in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). This growing incident population and the launches of several novel high-value agents will be the key drivers of market growth for CaB in Mexico through 2016. Mexico’s lack of legal requirement for clinical trials in the local population, as well as the progressive and well-informed physician community, offers significant opportunity to multinational companies (MNCs) with emerging therapies in this indication. In this report, we examine the trends within Mexico’s CaB therapy market, which is characterized by the widespread use of molecular testing, a near-universal healthcare system, and the anticipated uptake of several premium-priced therapies.

Questions Answered in This Report:

  *   Almost 60% of CaB cases in Mexico are diagnosed with late-stage disease. How does Mexico’s stage distribution at diagnosis compare that in the major markets? Will Mexico see changes in screening practices that will affect CaB stage distribution in the next five years? How does incidence of CaB translate into drug-treated CaB cases in Mexico?

  *   The majority of the surveyed oncologists in Mexico report following NCCN treatment guidelines for CaB. How similar is medical practice for the treatment of CaB in Mexico to that in the major markets? Do oncologists report significant constraints in access and reimbursement of targeted therapies? What has been the impact of the FDA’s decision to revoke bevacizumab’s CaB label on the drug’s uptake in Mexico?

  *   By 2016, five new therapies are expected to enter Mexico’s CaB market. How widely will these agents be used in Mexico and will they offer much competition to current therapies? What are Mexican oncologists’ perceptions of the emerging therapies, and how do they see them positioned against each other?

Scope:

Primary research: 90 oncologists surveyed across Mexico. Separate in-depth interviews with 8 oncologists from Mexico.

Epidemiology: Total incident cases as well as progressed incidence cases of CaB in Mexico over a ten-year period (2011-2021) by age and stage.

Current therapies and medical practice: Reporting use of brands and generics for the CaB treatments available in Mexico.

Pricing and reimbursement: Prices of CaB therapies in Mexico versus other major markets and analysis of the impact of government reimbursement on treatment trends.

Market forecast features: Our analysis evaluates rates of CaB progression and rates of drug treatment with CaB therapies across all stages of the disease. We include a detailed forecast of current and emerging therapies within the categories of selective estrogen receptor modulators, aromatase inhibitors, selective estrogen receptor downregulators, antimetabolites and other cytotoxics, anthracyclines, antitubulins, HER2-targeting agents, angiogenesis inhibitors, and mTOR inhibitors from 2011 through 2016, using an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - AstraZeneca
  • - Boehringer Ingelheim
  • - Bristol-Myers Squibb
  • - Celgene
  • - Janssen
  • - Eisai
  • - Eli Lilly
  • - Genentech
  • - GlaxoSmithKline
  • - Novartis
  • - Pfizer
  • - Pierre Fabre
  • - Puma Biotechnology
  • - Roche
  • - Sanofi
Decision Resources Group brands include: